Business Context and Reporting Period
Company: Broadstone Net Lease, Inc. (BNL)
Filing Type: Form 10-Q
Reporting Period: Quarter ended June 30, 2024
Business Overview: BNL is an industrial-focused, diversified net lease REIT investing in single-tenant commercial properties. As of June 30, 2024, the portfolio consisted of 777 properties across 44 U.S. states and four Canadian provinces, with 99.3% occupancy and a weighted average remaining lease term of 10.4 years.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Lease Revenues, Net | $105,907 | $109,353 | $211,274 | $228,345 |
| Net Income (GAAP) | $35,937 | $62,996 | $104,114 | $104,370 |
| Net Income Attributable to BNL | $35,329 | $60,014 | $100,443 | $99,318 |
| Diluted EPS | $0.19 | $0.32 | $0.53 | $0.53 |
| FFO (Funds From Operations) | $73,725 | $73,135 | $146,861 | $153,701 |
| AFFO (Adjusted FFO) | $70,401 | $70,873 | $141,276 | $136,489 |
| Net Cash from Operating Activities | N/A | N/A | $145,039 | $136,604 |
| Total Debt Outstanding | $1.907 billion | N/A | N/A | N/A |
| Net Debt | $1.887 billion | N/A | N/A | N/A |
| Cash and Cash Equivalents | $18,282 | N/A | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Lease revenues decreased 3.1% in Q2 2024 compared to Q2 2023, primarily due to the timing of dispositions in Q1 2024 and redeployment in Q2 2024. For the six months ended June 30, 2024, revenues decreased 7.5% year-over-year, driven by the absence of $7.5 million in lease termination fees recognized in the prior year.
- Impairment Charges: The company recognized a $3.9 million impairment charge in Q2 2024 (vs. $0 in Q2 2023) and $30.3 million for the six months ended June 30, 2024 (vs. $1.5 million in the prior year). These charges relate to the strategic decision to sell clinically-oriented healthcare properties.
- Gain on Sale of Real Estate: Gains on sales were $3.4 million in Q2 2024 compared to $29.5 million in Q2 2023. For the six-month period, gains increased to $62.5 million (vs. $32.9 million in 2023) due to the sale of 40 properties.
- Interest Expense: Interest expense decreased to $17.8 million in Q2 2024 from $20.3 million in Q2 2023, reflecting a decrease in average outstanding borrowings despite higher interest rates.
Guidance, Outlook, and Risks
- Portfolio Strategy: Management is executing a healthcare portfolio simplification strategy, selling clinically-oriented assets to redeploy capital into core verticals (industrial, retail, restaurant). Through June 30, 2024, 38 healthcare properties were sold for $262.2 million in gross proceeds.
- Liquidity: The company maintains an investment-grade balance sheet with a Net Debt to Annualized Adjusted EBITDAre ratio of 5.1x. As of June 30, 2024, there was $920.9 million of available capacity under the $1.0 billion Revolving Credit Facility.
- Dividends: A quarterly distribution of $0.29 per share was declared for Q3 2024, payable October 15, 2024.
- Risks: Key risks include interest rate volatility (mitigated by swaps covering significant variable debt), foreign exchange risk on Canadian investments, and the ability to redeploy capital at accretive yields in a challenging macroeconomic environment.
Investor Verification Checklist
- Healthcare Disposition Progress: Verify the completion of the remaining healthcare portfolio sales and the timing of capital redeployment into core sectors.
- Impairment Volatility: Monitor future quarters for additional impairment charges related to the healthcare strategy or other asset groups.
- Debt Maturities: Review the debt maturity schedule, noting the $400 million term loan and $79 million revolver maturing in 2026.
- Interest Rate Exposure: Assess the effectiveness of the $1.43 billion notional amount of interest rate swaps in hedging variable rate debt.
- Occupancy and Lease Expirations: Track the 10.4-year weighted average remaining lease term and the impact of lease expirations in 2024-2026 on renewal rates.